Supplementary Figure 4 from Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer

Autor:	Donald A. Bergstrom, Nina Baltes, Catherine Geslin, Loïc Vincent, Christophe Henry, Parminder K. Mankoo, Jack Pollard, Rebecca G. Bagley, Marielle Chiron
Rok vydání:	2023
DOI:	10.1158/1535-7163.22499839.v1
Popis:	PDF - 44K, Distribution of the tumor origin across PDX models: Of the 48 PDX tumors, 8 were derived from primary patient tumors, 36 from metastatic sites, 1 from a site of recurring disease, and 1 of unknown anatomical origin. All of the primary tumors (8/8) were associated with phenotype A where aflibercept is more efficacious than bevacizumab. PDX tumors that originated from metastatic tumors were represented in both phenotypes A (30/39) and B (9/9).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dacd48091d28a8602c397c34c181261 https://doi.org/10.1158/1535-7163.22499839.v1 Zobrazit plný text záznamu